Agilent and Seoul National University Hospital have announced a strategic collaboration for the development and verification of various biomarkers for the development of drugs, including narcotics, immune-suppressants and biomarkers. The hospital is one of Korea’s top medical centers.
“There are gaps in the medical industry that hamper the quality of care we can provide to patients,” said Prof. Byung-Hee Oh, president and CEO, Seoul National University Hospital. “One area we want to address is the development of biomarkers for early detection and effective monitoring of a range of diseases.”
Under the agreement, the hospital’s Department of Laboratory Medicine will use the Agilent 6460 Triple Quadrupole LC/MS system as well as Agilent’s support services and application expertise.
For more information go to: